Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

23.75 -0.31 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 327,093
Open 23.43
Bid (Size) 23.75 (2)
Ask (Size) 25.27 (1)
Prev. Close 24.06
Today's Range 23.34 - 24.28
52wk Range 18.69 - 35.73
Shares Outstanding 43,293,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into Regenxbio's Return On Capital Employed
 
Via Benzinga
5 Analysts Have This to Say About Regenxbio
 
Via Benzinga

Performance

YTD
+6.74%
+6.74%
1 Month
+4.03%
+4.03%
3 Month
+14.57%
+14.57%
6 Month
-32.22%
-32.22%
1 Year
-4.12%
-4.12%

More News

Read More
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Via FinancialNewsMedia
Exposures COVID-19
What 5 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
Via Benzinga
Recap: Regenxbio Q3 Earnings
Via Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Earnings Scheduled For November 3, 2022
Via Benzinga
Regenxbio's Earnings Outlook
Via Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
Via Benzinga
4 Analysts Have This to Say About Regenxbio
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Expert Ratings for Regenxbio
Via Benzinga
Regenxbio's Earnings Outlook
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Via Benzinga
5 Small-Cap S&P Stocks To Buy With The Most Upside
Via Benzinga
Regenxbio's Return On Capital Employed Overview
Via Benzinga
Expert Ratings for Regenxbio
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
83 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.